Differences Between Melanotan-I, II, and PT-141

Compound Comparisons

Differences Between Melanotan-I, II, and PT-141

Explore the differences between Melanotan-I, Melanotan-II, and PT-141, including their melanocortin receptor activity, effects on pigmentation, sexual-function pathways, appetite regulation, and distinct research applications.

ECP Research Team 13 min read
In this article8 sections
Key takeaways

Melanotan-I also known as MT-I or afamelanotide

Melanotan-II commonly abbreviated as MT-II

PT-141 also known as bremelanotide

Research use onlyEducational content for laboratory and research applications. Not medical or dosing advice.

The melanocortin system is a diverse peptide-signaling network involved in pigmentation, appetite, energy balance, sexual function, inflammation, and immune regulation.

Three commonly studied melanocortin peptides are:

  • Melanotan-I, also known as MT-I or afamelanotide
  • Melanotan-II, commonly abbreviated as MT-II
  • PT-141, also known as bremelanotide

Although these compounds share structural similarities and originate from the same melanocortin peptide family, they differ substantially in receptor selectivity, central nervous system activity, biological effects, and research applications.

Understanding these differences is important when selecting a compound for pigmentation, photoprotection, sexual-function, appetite, or receptor-specific melanocortin research.

For research use only. Not intended for human or veterinary use. This article is provided for scientific and educational purposes and does not constitute medical, therapeutic, cosmetic, performance-enhancement, formulation, or dosing advice.

What Is the Melanocortin System?

The melanocortin system begins with pro-opiomelanocortin, commonly abbreviated as POMC.

POMC is a large precursor protein that can be processed into several biologically active peptides, including:

  • Adrenocorticotropic hormone
  • Alpha-melanocyte-stimulating hormone
  • Beta-melanocyte-stimulating hormone
  • Gamma-melanocyte-stimulating hormone

These endogenous peptides act through a family of five G-protein-coupled receptors known as MC1R through MC5R.

Each receptor has a different tissue distribution and biological role.

The Five Melanocortin Receptors

MC1R

MC1R is expressed primarily in melanocytes, as well as in certain immune cells and hair-follicle-associated tissues.

Its functions include:

  • Melanin production
  • Eumelanin and pheomelanin balance
  • Pigmentation
  • Photoprotective responses
  • Inflammatory regulation
  • Immune-cell signaling

MC1R is the principal receptor involved in the pigmentation effects associated with Melanotan-I and Melanotan-II.

MC2R

MC2R is expressed primarily in the adrenal cortex.

It is unusual among melanocortin receptors because it is selectively activated by adrenocorticotropic hormone rather than by alpha-MSH-like peptides.

Its primary function is regulation of adrenal steroid production, including cortisol synthesis.

Melanotan-I, Melanotan-II, and PT-141 are not primarily used to study MC2R.

MC3R

MC3R is expressed in the hypothalamus, limbic regions, and certain peripheral tissues.

Research areas include:

  • Energy homeostasis
  • Feeding behavior
  • Nutrient partitioning
  • Inflammation
  • Metabolic regulation

MC3R activity contributes to some of the appetite and energy-balance effects associated with MT-II and PT-141.

MC4R

MC4R is widely expressed throughout the central nervous system, including the hypothalamus, brainstem, and spinal cord.

It is strongly associated with:

  • Appetite suppression
  • Energy expenditure
  • Sexual arousal
  • Erectile signaling
  • Genital responses
  • Neuroendocrine regulation

MC4R is central to the sexual-function research associated with Melanotan-II and PT-141.

MC5R

MC5R is expressed in several peripheral tissues, including exocrine glands.

Research areas include:

  • Sebaceous-gland activity
  • Lacrimal and salivary function
  • Immune regulation
  • Peripheral fat metabolism
  • Exocrine secretion

The different receptor distributions help explain why closely related melanocortin peptides can produce very different biological responses.

Alpha-MSH as the Natural Reference Peptide

Alpha-melanocyte-stimulating hormone, or alpha-MSH, is an endogenous melanocortin peptide derived from POMC.

It activates:

  • MC1R
  • MC3R
  • MC4R
  • MC5R

It does not activate MC2R.

The synthetic peptides discussed in this article are based on the alpha-MSH structure but contain modifications intended to increase stability, alter receptor selectivity, or improve biological duration.

What Is Melanotan-I?

Melanotan-I is a synthetic linear analog of alpha-MSH.

It is also known as:

  • MT-I
  • Afamelanotide
  • [Nle⁴, D-Phe⁷]-alpha-MSH

It retains much of the natural alpha-MSH sequence while incorporating two important amino-acid substitutions.

Melanotan-I Structure

Melanotan-I is a linear 13-amino-acid peptide.

Two modifications distinguish it from native alpha-MSH:

  1. Methionine at position 4 is replaced with norleucine
  2. L-phenylalanine at position 7 is replaced with D-phenylalanine

The norleucine substitution improves resistance to oxidation.

The D-phenylalanine substitution improves resistance to enzymatic degradation.

Together, these changes produce a more stable and longer-acting melanocortin analog while maintaining broad activity across several melanocortin receptors.

Melanotan-I Receptor Profile

Melanotan-I acts as an agonist at:

  • MC1R
  • MC3R
  • MC4R
  • MC5R

Its most prominent activity is generally associated with MC1R.

This receptor profile makes Melanotan-I particularly relevant to pigmentation, photoprotection, and skin-inflammation research.

Melanotan-I and Pigmentation

MC1R activation promotes the production of eumelanin.

Eumelanin is the darker form of melanin associated with:

  • Brown and black pigmentation
  • Increased UV absorption
  • Photoprotective responses
  • Reduced oxidative stress from ultraviolet exposure

Melanotan-I can stimulate melanogenesis independently of direct ultraviolet exposure.

This effect forms the basis of its most established clinical and research application.

Afamelanotide and Photoprotection Research

Afamelanotide is the pharmaceutical form of Melanotan-I.

It has been studied most extensively in conditions involving severe photosensitivity.

One important application is erythropoietic protoporphyria, a rare disorder in which accumulated porphyrin precursors can cause severe pain and skin reactions after light exposure.

Afamelanotide’s MC1R-mediated effects increase melanin production and improve photoprotection in this specific clinical setting.

The source material identifies afamelanotide as an approved product for erythropoietic protoporphyria. The approved pharmaceutical formulation should not be considered equivalent to unapproved research-grade Melanotan-I preparations.

Additional Melanotan-I Research Areas

Melanotan-I has also been investigated in relation to:

  • Vitiligo repigmentation
  • Solar urticaria
  • Polymorphic light eruption
  • UV-response biology
  • Melanocyte function
  • Skin photoprotection
  • Inflammatory skin signaling

These applications remain dependent on the condition, formulation, and study design.

Anti-Inflammatory MC1R Signaling

MC1R is expressed on more than melanocytes.

It has also been identified on immune-cell populations such as:

  • Macrophages
  • Dendritic cells
  • Monocytes
  • Certain lymphocyte populations

MC1R activation may influence inflammatory pathways, including:

  • NF-kappa B signaling
  • TNF-alpha production
  • IL-6 release
  • IL-1 beta signaling
  • Oxidative stress
  • Immune-cell activation

This creates a research rationale for studying Melanotan-I in inflammatory and immune-related models independently of pigmentation.

Central Nervous System Activity of Melanotan-I

Melanotan-I generally has less prominent central nervous system activity than Melanotan-II or PT-141.

Its larger linear structure may limit central penetration relative to smaller cyclic analogs.

Although MT-I can interact with MC3R and MC4R, its research profile is usually dominated by:

  • MC1R activation
  • Melanogenesis
  • Photoprotection
  • Skin biology

This makes it more suitable when researchers want to emphasize pigmentation while reducing central sexual or appetite-related confounders.

What Is Melanotan-II?

Melanotan-II is a smaller cyclic melanocortin analog.

It is derived from the active region of alpha-MSH and retains the same norleucine and D-phenylalanine substitutions found in Melanotan-I.

However, its shortened and cyclic structure produces different pharmacological characteristics.

Melanotan-II Structure

Melanotan-II is a cyclic heptapeptide.

Compared with Melanotan-I, it is:

  • Shorter
  • More structurally constrained
  • More resistant to enzymatic degradation
  • Better able to access central nervous system pathways
  • More strongly associated with MC4R-mediated effects

Cyclization reduces conformational flexibility and helps stabilize the structure that interacts with melanocortin receptors.

Melanotan-II Receptor Profile

Melanotan-II is a broad and relatively nonselective melanocortin agonist.

It has meaningful activity at:

  • MC1R
  • MC3R
  • MC4R
  • MC5R

Its receptor breadth resembles that of Melanotan-I, but its smaller cyclic structure produces more substantial central nervous system effects.

This makes MT-II relevant to several distinct research areas simultaneously.

Melanotan-II and Pigmentation

Like Melanotan-I, Melanotan-II activates MC1R and stimulates melanogenesis.

Research effects may include:

  • Increased eumelanin production
  • Darkening of skin pigmentation
  • Melanocyte activation
  • Altered UV responses
  • Changes in pigmentation distribution

However, MT-II is less selective for pigmentation-focused research because it also strongly activates central MC3R and MC4R pathways.

Melanotan-II and Sexual-Function Research

Melanotan-II became an important research compound after investigators observed that central melanocortin receptor activation could influence sexual responses.

Its effects are primarily associated with MC4R signaling in the brain and spinal cord.

Research areas include:

  • Erectile responses
  • Genital arousal
  • Sexual motivation
  • Hypothalamic signaling
  • Spinal pro-arousal pathways
  • Oxytocin-related signaling

These effects differ fundamentally from the peripheral vascular mechanism associated with phosphodiesterase type 5 inhibitors.

Central vs. Peripheral Sexual Signaling

Peripheral sexual-function drugs generally act by changing vascular tone and blood flow.

Melanocortin agonists act more centrally.

MC4R activation may influence:

  • Sexual motivation
  • Central arousal
  • Hypothalamic activation
  • Autonomic signaling
  • Spinal erectile pathways
  • Genital response coordination

This distinction eventually contributed to the development of PT-141 as a more targeted melanocortin compound.

Melanotan-II and Appetite Research

MC3R and MC4R play major roles in feeding behavior and energy homeostasis.

Melanotan-II has therefore been studied in models involving:

  • Appetite suppression
  • Reduced food intake
  • Energy expenditure
  • Obesity biology
  • Hypothalamic feeding circuits
  • Metabolic regulation

Its broad receptor activity can be useful when studying the melanocortin system as a whole.

However, simultaneous activation of pigmentation and sexual-function pathways may complicate interpretation.

Advantages and Limitations of Melanotan-II

The major advantage of MT-II is its broad activity.

It can be used to examine several melanocortin pathways within one model.

The major limitation is the same lack of selectivity.

Observed effects may result from activation of:

  • MC1R
  • MC3R
  • MC4R
  • MC5R
  • Multiple receptors simultaneously

This can make receptor-specific conclusions difficult without appropriate antagonists, genetic models, or selective control compounds.

What Is PT-141?

PT-141, also known as bremelanotide, is a cyclic melanocortin peptide closely related to Melanotan-II.

It was developed after the central sexual effects of MT-II were identified.

PT-141 retains strong activity at central melanocortin receptors while producing less prominent pigmentation than MT-II.

PT-141 Structure

PT-141 is a cyclic heptapeptide related to Melanotan-II.

A relatively small structural change alters its receptor behavior and functional profile.

The resulting compound retains meaningful activity at:

  • MC3R
  • MC4R

Its MC1R-mediated pigmentation activity is reduced relative to Melanotan-II.

This makes PT-141 more appropriate for studies emphasizing central melanocortin signaling while minimizing pigmentation as an experimental confound.

PT-141 Receptor Profile

PT-141 is functionally associated primarily with:

  • MC4R
  • MC3R

It has lower melanogenic activity than MT-I or MT-II.

Its main research areas include:

  • Sexual motivation
  • Sexual arousal
  • Erectile signaling
  • Hypothalamic pathways
  • Appetite regulation
  • Energy balance
  • Central melanocortin biology

It is the most functionally selective of the three compounds for central melanocortin research.

PT-141 and Sexual-Function Research

PT-141 acts through central nervous system pathways rather than directly through peripheral vasodilation.

Research has examined its influence on:

  • Sexual desire
  • Sexual motivation
  • Genital arousal
  • Hypothalamic activation
  • MC4R signaling
  • Erectile pathways
  • Female sexual-function biology
  • Male sexual-function biology

This central mechanism distinguishes it from compounds that act primarily through nitric oxide and cyclic GMP signaling.

Bremelanotide as an Approved Drug

Bremelanotide is the active compound in an approved pharmaceutical product used for a specific sexual-function indication in premenopausal women.

That approval applies to the regulated pharmaceutical formulation and its labeled indication.

It does not establish the safety, quality, equivalence, or intended use of research-grade PT-141 products.

Research involving other populations or outcomes should not be treated as an approved therapeutic application.

PT-141 and Appetite Regulation

Because PT-141 retains activity at MC3R and MC4R, it has also been investigated in appetite and metabolic research.

Research areas may include:

  • Food intake
  • Satiety
  • Hypothalamic signaling
  • Energy expenditure
  • Obesity-related pathways
  • Central nutrient sensing

Its reduced pigmentation activity can make it more useful than MT-II when researchers want to isolate central melanocortin effects.

Melanotan-I vs. Melanotan-II vs. PT-141

PropertyMelanotan-IMelanotan-IIPT-141
Common nameMT-I or afamelanotideMT-IIBremelanotide
StructureLinear 13-amino-acid analogCyclic heptapeptideCyclic heptapeptide
Primary research emphasisPigmentation and photoprotectionBroad melanocortin activityCentral sexual and appetite pathways
MC1R activityHighHighReduced
MC3R activityPresentHighHigh
MC4R activityPresentHighHigh
MC5R activityPresentPresentLower
CNS activityMore limitedProminentProminent
Pigmentation effectPrimarySignificantReduced
Sexual-function activityLess prominentStrongStrong and more targeted
Appetite researchSecondaryRelevantRelevant
Main limitationLess suitable for isolated CNS researchBroad and difficult to separateDoes not model full melanocortin receptor activity

Selecting Melanotan-I for Research

Melanotan-I is generally the most appropriate of the three when the experimental objective involves:

  • MC1R biology
  • Melanin synthesis
  • Eumelanin production
  • Photoprotection
  • UV-response research
  • Melanocyte signaling
  • Inflammatory skin pathways
  • Pigmentation with fewer CNS confounders

Its primary strength is its established relationship with pigmentation and photoprotection.

Selecting Melanotan-II for Research

Melanotan-II may be appropriate when the research question requires broad activation of several melanocortin pathways.

Potential applications include:

  • Combined pigmentation and CNS research
  • MC1R and MC4R comparisons
  • Sexual-arousal signaling
  • Appetite suppression
  • Energy balance
  • Whole-system melanocortin pharmacology
  • Receptor interaction studies

Its nonselectivity should be considered during study design.

Selecting PT-141 for Research

PT-141 is generally better suited to research focused on:

  • MC4R signaling
  • MC3R signaling
  • Central sexual motivation
  • Genital arousal pathways
  • Erectile signaling
  • Appetite control
  • Energy balance
  • CNS melanocortin function
  • Reduced pigmentation confounding

It provides a cleaner central melanocortin profile than MT-II, although it is not completely receptor-specific.

Pigmentation Research

Pigmentation research primarily centers on MC1R.

Activation of MC1R in melanocytes influences:

  • Tyrosinase activity
  • Melanin synthesis
  • Melanosome production
  • Eumelanin formation
  • Pigment transfer
  • UV-response pathways

Melanotan-I and Melanotan-II are both relevant, but MT-I is more closely associated with photoprotection-focused research.

Sexual-Function Research

Sexual-function research primarily emphasizes MC4R and central nervous system pathways.

MT-II and PT-141 may influence:

  • Hypothalamic arousal circuits
  • Spinal sexual reflexes
  • Autonomic output
  • Oxytocin-related pathways
  • Sexual motivation
  • Genital responses

PT-141 is generally used when minimizing MC1R-mediated pigmentation is important.

Appetite and Energy-Balance Research

MC3R and MC4R participate in hypothalamic pathways that regulate food intake and energy expenditure.

Research endpoints may include:

  • Meal size
  • Food-seeking behavior
  • Satiety
  • Body-weight changes
  • Energy expenditure
  • Glucose regulation
  • Lipid metabolism
  • Hypothalamic neuronal activation

MT-II and PT-141 are more relevant to these questions than MT-I.

Inflammation and Immune Research

Melanocortin signaling may influence inflammatory pathways through several receptors.

MC1R, MC3R, and MC5R have all been investigated in relation to:

  • Cytokine production
  • Macrophage activation
  • Neutrophil migration
  • NF-kappa B activity
  • Tissue inflammation
  • Immune-cell regulation

MT-I may be particularly useful for MC1R-focused inflammatory research, while broader compounds may produce effects through multiple receptor types.

Receptor Selectivity and Experimental Controls

None of these compounds should be assumed to act through only one receptor.

Researchers may need controls such as:

  • Receptor-selective antagonists
  • Receptor-knockout models
  • Gene-silencing methods
  • Competitive binding studies
  • Pathway-specific biomarkers
  • Comparison compounds
  • Vehicle controls

Without these controls, it may be difficult to determine which melanocortin receptor produced an observed effect.

Central Nervous System Penetration

Structural differences influence the ability of these peptides to access central pathways.

Melanotan-II and PT-141 are smaller cyclic compounds and are associated with stronger CNS effects.

Melanotan-I is a longer linear peptide and is generally less prominent in CNS-focused research.

However, CNS exposure can depend on:

  • Route of administration
  • Species
  • Peptide stability
  • Dose
  • Blood-brain barrier conditions
  • Experimental model

Structural predictions alone do not fully establish tissue distribution.

Pharmacological Selectivity vs. Functional Selectivity

A compound may activate several receptors in a binding assay but appear more selective in a living system because of:

  • Tissue distribution
  • Receptor expression
  • CNS penetration
  • Metabolism
  • Local concentration
  • Receptor reserve
  • Signal amplification

PT-141 is often described as functionally selective for central sexual pathways because its pigmentation effect is reduced compared with MT-II.

This does not mean it activates only MC4R.

Research Quality Considerations

Research-grade melanocortin peptides should be supported by batch-specific analytical documentation.

Useful information may include:

  • Peptide name
  • Amino-acid sequence
  • Molecular weight
  • HPLC purity
  • Mass-spectrometry identity
  • Peptide content
  • Counterion form
  • Lot number
  • Endotoxin testing
  • Sterility testing where relevant
  • Stability data
  • Storage conditions

A purity percentage alone does not confirm receptor activity or biological potency.

Laboratory Handling

Melanotan-I, Melanotan-II, and PT-141 are commonly supplied as lyophilized research peptides.

Laboratories should follow product-specific documentation concerning:

  • Reconstitution
  • Diluent selection
  • Storage temperature
  • Light protection
  • Working-solution stability
  • Container compatibility
  • Freeze-thaw limitations
  • Microbial control
  • Disposal procedures

Generalized handling instructions should not replace manufacturer documentation or an approved institutional protocol.

Peptide Stability

Peptide stability may be affected by:

  • Heat
  • Light
  • Oxygen
  • pH
  • Moisture
  • Enzymatic degradation
  • Surface adsorption
  • Repeated freeze-thaw cycles
  • Microbial contamination

The stability of the lyophilized peptide may differ substantially from that of a prepared solution.

Research Limitations

Important limitations include:

  • None of the compounds is completely receptor-specific
  • MT-II activates several pathways simultaneously
  • PT-141 retains more than one melanocortin receptor interaction
  • CNS penetration varies by experimental system
  • Pigmentation responses differ by baseline melanocyte biology
  • Species differences can affect receptor pharmacology
  • Approved pharmaceutical formulations are not equivalent to research-grade products
  • Binding affinity does not always predict functional response
  • Long-term receptor activation may lead to desensitization
  • Preclinical findings do not automatically translate to humans

Conclusion

Melanotan-I, Melanotan-II, and PT-141 are structurally related melanocortin peptides with meaningfully different research profiles.

Melanotan-I is most closely associated with MC1R-mediated pigmentation, melanogenesis, photoprotection, and skin-inflammation research.

Melanotan-II is a broad-spectrum melanocortin agonist with substantial activity in both peripheral pigmentation pathways and central sexual and appetite-regulation pathways.

PT-141 retains strong central MC3R and MC4R activity while producing less prominent pigmentation, making it more appropriate for research involving sexual motivation, arousal, appetite, and CNS melanocortin signaling.

Choosing among the three requires understanding the receptor pathway being studied, the desired degree of central activity, and whether pigmentation or other off-target effects would complicate the experimental model.

For research use only. Not intended for human or veterinary use. This article is provided for scientific and educational purposes and does not constitute medical, therapeutic, cosmetic, performance-enhancement, formulation, reconstitution, or dosing advice.

Continue your research

Explore compounds with clarity.

Review the ECP catalog alongside clear product information and available quality documentation.

Leave a Reply

This product is currently sold out. Don't worry! Enter your email and we'll notify you when it's available again.